<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892137</url>
  </required_header>
  <id_info>
    <org_study_id>LP0041-62</org_study_id>
    <nct_id>NCT01892137</nct_id>
  </id_info>
  <brief_title>Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%</brief_title>
  <official_title>Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to demonstrate the predictive value of the clinical
      diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using
      histopathological examination as the standard.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of AK</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary response criterion is the clinical and histological clearance of AK at Day 57. Clinical Clearance will be measured by counting AKs, and histological clearance will be by performing a biopsy (result reported as AK or not AK).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance of AKs in the Selected Treatment Area</measure>
    <time_frame>8 weeks</time_frame>
    <description>Efficacy in terms of complete clearance of AKs in the STA and histological clearance of pre-identified lesion. AK clearance will be determined by AK count. Clearance of the pre-identified lesion will be assessed by a histopatholgist from a biopsy sample and reported as AK or not AK.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Open label active</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol mebutate gel 0.05%</intervention_name>
    <description>Once daily for 2 consecutive days</description>
    <arm_group_label>Open label active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female and at least 18 years of age.

          -  Female patients must be on non-childbearing potential or if of childbearing potential
             then negative serum and urine pregnancy test and using effective contraception

          -  Ability to provide informed consent

          -  Subjects must have 5-9 clinically typical, visible and discrete AK lesions within a
             contiguous 25cm2 treatment area on the trunk and extremities except the back of the
             hand

          -  AK should be confirmed by histopathology of one of the AK's prior to inclusion

        Exclusion Criteria:

          -  location of the selected treatment area within 5cm of an incompletely healed wound or
             within 10cm of a suspected basal cell carcinoma or squamous cell carcinoma

          -  undergone Cosmetic or therapeutic procedures

          -  use of acid-containing therapeutic products within 2cm of the selected treatment area
             in the 2 weeks prior to Visit 1

          -  use of topical creams/lotions, artificial tanners or topical steroids within 2cm of
             the selected treatment areas in the 2 weeks prior to visit 1.

          -  treatment with immunomodulators, or interferon/interferon inducers or systemic
             medications that suppress the immune system within 4 weeks of visit 1

          -  treatment with 5-FU, imiquimod, diclofenac, ingenol mebutate of photodynamic therapy
             within 2cm of the treatment area in the 8 weeks prior to visit 1

          -  use of systemic retinoids

          -  those who are currently participating in any other interventional clinical trial

          -  females who are pregnant or are breastfeeding

          -  those known or suspected of not being able to comply with the requirements of the
             protocol or provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Ulrich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum Berlin GmbH, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southderm Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia</name>
      <address>
        <city>north Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South East Dermatology Centre</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St John of God Dermatology</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie &amp; Allergologie Klinikum Augsburg Süd</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collegium Medicum Berlin GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Prof. Dr. med. C. Termeer</name>
      <address>
        <city>Stuttgart</city>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leopharma.com</url>
    <description>LEO Pharma</description>
  </link>
  <link>
    <url>http://www.tga.gov.au</url>
    <description>Therapeutic Goods Administration</description>
  </link>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2013</study_first_submitted>
  <study_first_submitted_qc>June 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Histopathology</keyword>
  <keyword>Reflectance Confocal Microscopy</keyword>
  <keyword>Local Skin Reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

